Pharmacology News

Psychopharmacology Masterclass: Drug Classes, Mechanisms of Action, and What Every Psychologist Needs to Know for Clinical Practice and the

Psychopharmacology is one of the most heavily tested and clinically consequential domains in professional psychology, covering everything from the neurochemical mechanisms behind antidepressants, antipsychotics, mood sta

Noribogaine (DMX-1001): A Neuroplastogen Breakthrough for Alcohol Use Disorder or Another Psychedelic Promise with Risks?

The FDA accepted DemeRx’s IND for oral noribogaine (DMX-1001) in April 2026, advancing a longer-acting metabolite of ibogaine as a potential treatment for alcohol use disorder (AUD) through neuroplasticity and polypharma

Rising Costs in Healthcare: The 2026 Pharmaceutical Price Increases and Their Implications

I n early 2026, pharmaceutical manufacturers announced list price increases on at least 350 brand-name medications, continuing a pattern that affects treatments for cancer, COVID-19, migraines, and other conditions despi

The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 2

Part two In the mid-20th century, a handful of chance observations transformed psychiatry from an asylum-bound specialty into a medical field powered by effective drugs. This episode explores how chlorpromazine emerged f

The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 1

In the mid-20th century, a handful of chance observations transformed psychiatry from an asylum-bound specialty into a medical field powered by effective drugs. This episode explores how chlorpromazine emerged from indus

Curcumin: Turmeric’s Golden Promise for Blood Sugar and Mood – Evidence, Arguments For and Against

Explore the 2026 meta-analysis and supporting studies on curcumin for prediabetes, type 2 diabetes, depression, and anxiety, weighing compelling arguments in favor of its use against important limitations and counterpoin

Dextromethorphan ( think cough syrup) for OCD: A Promising Glutamate-Targeted Augmentation Strategy?

A small 2026 randomized controlled trial found that adding low-dose dextromethorphan (DXM, 15 mg twice daily) to ongoing SSRI treatment significantly reduced Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores in adult

Antidepressants and Suicide Prevention: Lessons from Korea’s 2002 Prescription Restrictions

A recent study examines how South Korea’s 2002 limits on SSRI prescribing by primary care physicians coincided with a striking rise in national suicide rates. This episode reviews the Korean evidence alongside internatio

Silent Slip: How Medications Are Fueling Falls in Our Elderly

This episode explores the alarming link between common medications and falls among older adults, revealing how psychotropics and polypharmacy contribute to up to three-quarters of incidents in nursing homes. Drawing on k

The Dangerous Tetrad: Mastering the Fatal Signs of Rigidity and Fever -case study

In the ER, seconds matter when identifying the "Dangerous Tetrad": rigidity, fever, autonomic instability, and altered mentation. This episode breaks down the clinical markers and pathophysiology of these life-threatenin

Antidepressant Withdrawal: 50% of Long-Term Users Suffer? Shocking JAMA Study vs Real-World Reality Exposed

Psychiatrists are clashing over antidepressant withdrawal: clinic data shows up to 50% of long-term SSRI/SRI users face severe symptoms, while a major 2025 JAMA Psychiatry meta-analysis claims they’re usually mild and br

Metabolic Brake or Muscle Catalyst? The Pharmacokinetics of GLP-1 Muscle Loss

While GLP-1 receptor agonists are not inherently "muscle-toxic," the rapid metabolic shift they induce can lead to a catabolic state that consumes lean tissue. In this episode, we dive into the pharmacology of semaglutid

Ibogaine: Miracle Cure or Medical Gamble? The Truth Behind a Controversial Psychedelic

This episode explores ibogaine as a controversial psychedelic treatment for addiction, examining its reported effects on opioid withdrawal, cravings, and psychological insight alongside serious cardiac and neurological r

Low-Dose Methamphetamine Neuroprotection: What the Studies Actually Show

The Messy Truth About Antidepressants: Benefits, Risks, and the Limits of the Evidence

Antidepressants demonstrate modest but real benefits for moderate-to-severe depression, with large meta-analyses showing consistent advantages over placebo and meaningful improvements in function for many patients, yet t

Why One ADHD Medication Hits Kids So Differently — And How Genetics Can Help

Artificial intelligence begins prescribing medications in Utah

Marijuana and emphysema

Ketamine and neurotoxicity

New study on lithium